Dear Sir, Homozygous expansions greater than 66 repeat lengths of a GAA repeat in the first intron of the X25 /frataxin gene have been linked with the development of Friedreich's ataxia (FRDA) [1]. Abnormal glucose tolerance is present in 30 % of FRDA patients, with about 10 % having overt diabetes [2]. Intermediate GAA repeat expansions (10±36 repeats) do not lead to the FRDA phenotype but a recent case control study reported an increased prevalence in Type II (non-insulin-dependent) diabetes mellitus [3]. This has not been replicated in subsequent studies [4±6], although non-diabetic carriers of the intermediate expansion were found to have abnormal insulin secretion [6].
Dear Sir, Homozygous expansions greater than 66 repeat lengths of a GAA repeat in the first intron of the X25 /frataxin gene have been linked with the development of Friedreich's ataxia (FRDA) [1] . Abnormal glucose tolerance is present in 30 % of FRDA patients, with about 10 % having overt diabetes [2] . Intermediate GAA repeat expansions (10±36 repeats) do not lead to the FRDA phenotype but a recent case control study reported an increased prevalence in Type II (non-insulin-dependent) diabetes mellitus [3] . This has not been replicated in subsequent studies [4±6] , although non-diabetic carriers of the intermediate expansion were found to have abnormal insulin secretion [6] .
These studies exploring the importance of intermediate expansions in Type II diabetes have all been case control studies, which are susceptible to the generation of spurious results due to population stratification. A family-based association method using parent-offspring trios can overcome this problem as it detects only those associations due to linkage [7] . This approach also allows parent-of-origin effects to be examined, which case control studies cannot detect [7] . This is particularly relevant to FRDA as intergeneration expansion of the GAA repeat has only been reported with maternally transmitted alleles [8] , and larger expansions are associated with a more severe clinical phenotype [2] .
We have therefore examined the importance of intermediate GAA expansions in Type II diabetes using the British Diabetic Association-Warren 2 Trio collection which comprises parent-offspring trios ascertained through Type II diabetic probands with both parents alive [7] . After exclusion of known subtypes of diabetes (mitochondrial-related diabetes, maturity-onset diabetes of the young, and late-onset autoimmune diabetes) and families with inconsistent family relationships, 155 parent-offspring trios were available for study. Identification of the intermediate expansion was carried out using a PCR-based technique [3] .
Screening of the diabetic offspring showed that 37 (24 %) were carriers of intermediate expansions. Table 1 summarises the transmission data and shows that 75 parents were heterozygous carriers of which 40 (53 %) transmitted the intermediate expansion to their diabetic offspring (p = 0.64, assuming expected 50 % transmission). Considering parent-of-origin effects, one parent-offspring trio had to be excluded because parent of origin could not be assigned as all were heterozygous carriers of the same sized expansion. As shown in Table 1 Treatment with insulin-sensitizing agents, such as metformin, has been shown to reduce insulin resistance, to statistically significantly decrease androgen concentrations and to initiate menstrual cyclicity in these patients [3] . These effects are consistent with the hypothesis that hyperinsulinaemia and insulin resistance have an aetiological role in hyperandrogenism through stimulation of ovarian and adrenal steroidogenesis.
We report the results of a 10-month treatment with metformin (850 mg twice daily) in a lean (body mass index, 20 Kg/m 2 ), girl aged 13 years 6 months with severe hirsutism, acne, clitoral hypertrophy, acanthosis nigricans and primary amenorrhea. Basal hormonal assessment showed high total serum testosterone, 17-hydroxyprogesterone, androstenedione, immunoreactive insulin concentrations and decreased sex hormone-binding globulin concentrations. A tumoral origin of the hyperandrogenism was ruled out by appropriate imaging studies. Short-term leuprolide acetate stimulation (Procrin, Abbott, Madrid, Spain, 500 mg, s.c), elicited an increase in ovarian 17-hydroxyprogesterone concentrations (30.6 nmol/l) suggestive of functional ovarian hyperandrogenism. A standard oral glucose tolerance test produced insulin peaks of more than 3587 pmol/l at all time points, with normal glucose tolerance.
Molecular analysis of the insulin receptor gene showed a heterozygous novel missense mutation in exon 17 of the insulin receptor gene (Ala1028 ®Val) abolishing autophosphorilation of the insulin receptor b-subunit.
Basal androgens and fasting insulin concentrations decreased significantly during treatment whereas sex hormonebinding globulin concentrations increased (Table 1) . Breast development progressed and menarche occurred in the fifth month of therapy. No side-effects were documented.
Metformin is a biguanide hypoglycaemic agent that increases peripheral utilization of glucose, acting in the early steps of insulin signal transduction through potentiating phosphatidylinositol-3' kinase pathway of insulin receptors [4] and decreasing ovarian and adrenal cytochrome P450c17 activity [3] . Prolonged treatment with metformin has been proved to be safe in Type II (non-insulin-dependent) diabetes mellitus and in a pregnant hyperandrogenic woman [5] . Metformin, troglitazone (a thiazolidinedione derivative) and the d-chiroinositol-containing phosphoglycan mediator of the action of insulin, reduce hyperinsulinism and hyperandrogenism in women with functional ovarian hyperandrogenism. The new agent L-783,281, recently identified as a non-peptidyl fungal metabolite, seems to act by stimulating tyrosine kinase activity of insulin receptors [7] . Although this drug might have beneficial effects in insulin resistance states due to insulin receptor mutations in the a-subunit, it might be ineffective in tyrosin kinase domain mutations of the insulin receptor in which this activity is abolished.
Our results show the usefulness and safety of metformin therapy in an adolescent with type A insulin resistance syndrome associated with severe hyperandrogenism. Normal values for age-matched control girls (mean ± SD; n = 40): TT, 0.7 ± 0.3 nmol/l; SHBG, 59.0 ± 6.9 nmol/l; 17-OHP, 1.8 ± 0.01 nmol/l; D 4 -A, 4.4 ± 1.7 nmol/l; insulin, 35.9±107.6 pmol/l
